Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Colorectal Neoplasms 4Parkinson Disease 4, Autosomal Dominant Lewy Body 3Ovarian Neoplasms 3Fallopian Tube Neoplasms 2Uterine Cervical Neoplasms 1Sarcoma, Alveolar Soft Part 1Rectal Neoplasms 1Rectal Diseases 1Neoplasms 1Intestinal Neoplasms 1Intestinal Diseases 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Colonic Neoplasms 1Colonic Diseases 1Carcinoma, Ovarian Epithelial 1Carcinoma, Hepatocellular 1Brenner Tumor 1

Interventions

Taxes 1Paclitaxel 1Immunoglobulin G 1Disulfides 1Carboplatin 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × Brenner Tumor × Bevacizumab × Clear all
NCT00262847 2019-07-23

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

National Cancer Institute (NCI)

Phase 3 Completed
1,873 enrolled 17 charts 1 FDA
Gynecologic

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡